In July, 2000, our working on group on ICH E-11 completed its task of writing a document designed to harmonize pediatric drug development. I was honored to serve as the rapporteur for this effort. By way of full disclosure, Dr Dianne Murphy, who is an author of the paper ''A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA from 2007-2013'' in this issue of TIRS, was on the committee as well. She has also been a valued colleague of mine through the years, and will retire this year after a distinguished career at FDA where she has been a tireless champion for the needs of sick children.
What were our hopes for ICH E-11 16 years ago? All of us were focused on the need to harmonize pediatric drug development globally, to continuously improve the scientific basis of pediatric clinical trials, to assure the highest ethical standards in pediatric studies, and ultimately, to provide the best information on the safe and effective use of medicines in children. We believed that harmonization would lead to more international studies, less duplication of studies, and thus, a more ethical framework of entering nonconsenting subjects in the most needed and well-designed clinical trials. We were well aware of different legal frameworks under which our agencies were constituted and function, as well as sociocultural differences in disease definition and prevalence. Our ''precision'' as pediatricians in diagnosis, in understanding pathogenesis, and in evaluating outcomes of therapy was wanting. We were honest in our discussions of what we did not know as much as what we considered to be validated science.
The previously referenced article in this issue of TIRS provides some important insights into how we have done in one aspect of pediatric drug regulation, that is, the granting of ''waivers'' in situations where pediatric studies on new drugs could not or should not be done. It is worth mentioning that the pediatric committees of the EMA and FDA hold frequent phone conferences and share challenges and insights with each other. This ongoing communication has been invaluable in advancing the field of pediatric therapeutics and has highlighted both the similarities, and sometimes the differences, in approaches to pediatric drug regulation between the agencies. The outcomes of the current review are striking. Despite differences in law, requirements, incentives, and culture, the vast majority of decisions by EMA and FDA about waivers have been, as stated in the article, ''remarkably similar.'' It is worthwhile to read this article in depth, reviewing the tables and text, to gain understanding of the processes that affect decision making in this sphere. There is good discussion of those products for which disparate decisions were reached and why, as well as how harmonization has indeed helped address and overcome what could have been very different decisions. Understanding and discussing the processes of regulation in the EMA and FDA for pediatrics has broad implications for all regulatory science.
We live in a time when discussions of ''precision'' medicine are quite rightly among the hottest topics in diagnostics and therapeutics. This article should make us remember that in all aspects of medicine, and I suppose in life in general, we must make decisions absent all the information that we would like to have, that we will never know everything, and that we need processes that openly and transparently illuminate uncertainties and our differences in approaches to problem solving. As Robert Frost put it, ''We dance round in a ring and suppose, but the secret sits in the middle and knows.' ' We can only hope that discussion, analysis of outcomes, and working together can further optimize how we approach medical and regulatory science, how we can better serve all in need. The current paper suggests that good science can lead to substantial agreement on essential issues. Thoughtful discussion of differences can lead to further advancement in real-world therapeutics on all sides. 
